

## Special Issue

# Regulatory T Lymphocytes: Three Decades with Odette- and-Odile in Human Diseases

### Message from the Guest Editor

Responses of the immune system are controlled by regulatory mechanisms guided by specific immunoreactive and suppressive cellular compartments, including regulatory lymphocytes, macrophages, and myeloid-derived suppressor cells. The first described immune cell population with regulatory properties was the regulatory T cells (Tregs), almost 30 years ago. Since the first report on their implication in the development of autoimmunity in experimental models, Tregs have attracted great research interest and have been proven pivotal players in any condition where the control of immune response may be critical.

In vivo and in vitro experiments have revealed their implication in the development and perpetuation of human disorders in the fields of autoimmunity, cancer, allergy, asthma, and others, and indicated their potential as possible therapeutic targets. In this commemorative Special Issue, we welcome submissions of research works on the involvement of Tregs in any human disorder where the immune microenvironment plays a key pathogenetic role, and/or on their capacity to enhance the diagnostic and therapeutic clinical armamentarium.

### Guest Editor

Dr. Maria-Ioanna Christodoulou

1. Department of Life Sciences, European University Cyprus, Nicosia 2404, Cyprus

2. School of Infection and Immunity, University of Glasgow, Glasgow G12 8TA, UK

### Deadline for manuscript submissions

closed (31 May 2024)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/123228](https://mdpi.com/si/123228)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).